Literature DB >> 7706789

Use and safety of acellular pertussis vaccine among adult hospital staff during an outbreak of pertussis.

A Shefer1, L Dales, M Nelson, B Werner, R Baron, R Jackson.   

Abstract

During May and June 1993, 10 patients and 5 members of the clinical staff at a hospital in California were diagnosed with Bordetella pertussis infection. In addition to erythromycin prophylaxis, 630 (48%) of 1330 staff members received a half dose of acellular pertussis vaccine with tetanus and diphtheria toxoids (DTaP). To identify side effects of the vaccine, a questionnaire was completed by 344 (54%) of 630 vaccinated staff. Side effects were reported by 117 respondents (34%); 64 were classified as mild (local reaction at injection site) and 50 as moderate (systemic complaints or local reaction resulting in limitation of arm movement). Three vaccinees (< 1%) reported missing 1 or more days of work because of their symptoms. Local reactions at the injection site occurred in 100 (29%), systemic symptoms in 38 (11%), and limitation of arm movement in 18 (5%). This study indicates that use of half dose of DTaP in adults appears safe and should be considered as an adjunct to chemoprophylaxis during institutional outbreaks.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706789     DOI: 10.1093/infdis/171.4.1053

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Infections Associated with Health-care Personnel: Vaccine-preventable Diseases and Bloodborne Pathogens.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

Review 2.  Pertussis vaccination for health care workers.

Authors:  Thomas J Sandora; Courtney A Gidengil; Grace M Lee
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

3.  Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark
Journal:  MMWR Recomm Rep       Date:  2018-04-27

Review 4.  Acellular pertussis vaccines. Towards an improved safety profile.

Authors:  M E Pichichero
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

5.  Management of vaccine safety in Korea.

Authors:  Young June Choe; Geun-Ryang Bae
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15

6.  Seroprevalence of pertussis antibody among health care personnel in Spain.

Authors:  Jose-Ramón de Juanes; Angel Gil; Antonio González; María-Pilar Arrazola; María San-Martín; Jesús Esteban
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.